UroGen Pharma Ltd

Stock Chart, Company Information, and Scan Results

$18.80(as of Sep 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

UroGen Pharma Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$18.80
Ticker SymbolURGN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees253
CountyUSA
Market Cap$903.5M
EBIDTA-122.2M
10-Day Moving Average19.37
P/E Ratio-5.97
20-Day Moving Average19.28
Forward P/E Ratio0.00
50-Day Moving Average17.21
Earnings per Share-3.01
200-Day Moving Average12.05
Profit Margin-206.24%
RSI55.68
Shares Outstanding46.3M
ATR1.02
52-Week High21.02
Volume1,011,700
52-Week Low3.42
Most Recent Support Level18.75
Book Value-93.4M
Most Recent Resistance Level20.20
P/B Ratio-9.90
Upper Keltner21.59
P/S Ratio9.81
Lower Keltner16.98
Debt-to-Equity Ratio21.59
Next Earnings Date11/17/2025
Cash Surplus45.4M
Next Ex-Dividend DateUnknown

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Ltd In Our Stock Scanner

As of Sep 04, 2025
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Channel Pattern RangeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.